Home / Generics / News / Teva launches ulcerative colitis generic in the US

Teva launches ulcerative colitis generic in the US Posted 27/04/2018

Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 26 March 2018 that it had launched generic mesalamine delayed-release tablets (1.2 g) in the US.

Teva’s generic mesalamine tablets are a generic alternative to Lialda [mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA)], is an aminosalicylate anti-inflammatory drug indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.

According to the Centers for Disease Control and Prevention (CDC), more than a million people in the US are estimated to suffer from inflammatory bowel diseases, including ulcerative colitis.

Mesalamine delayed-release tablets (1.2 g) had 2017 annual sales of approximately US$1.11 billion in the US, according to IMS data.

Teva claims to have the largest portfolio of US Food and Drug Administration approved generics on the market and states that it has nearly 600 generics available in the US. The company also claims to hold the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Teva adds that ‘currently, one in seven generic prescriptions dispensed in the US is filled with a Teva generic product’.

Related articles
Teva sells Actavis UK and Ireland generics business to Intas

Teva to acquire US-based generics distributor Anda

Teva launches generic acamprosate in US

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Teva, US CDC

Comments (0)